Fibrinolysis in Disease - The Malignant Process, Interventions in Thrombogenic Mechanisms,

List of contents

Part 1: The Role of the Plasminogen Activation System in Neoplasia
1. uPA Production, Receptor Display, and Differentiation
D. Boyd and M. Brattain
2. Interactions between Epidermal Growth Factor and Its Receptor in the Regulation of Urokinase Plasminogen Activator in Normal and Malignant Keratinocytes
M.J. Niedbala and A.C. Sartorelli
3. Tissue-Type and Urokinase-Type Plasminogen Activators as Prognostic Markers in Breast Cancer
M.J. Duffy et al.
4. Both uPA and PAI-1 Are Independent Prognosticators of Relapse and Death in Breast Cancer
F. Jänicke, M. Schmitt, and H. Graeff
5. PAI-1 and PAI-2 Levels as Predictors in Staging Malignancy in Breast Cancer
K. Sumiyoshi et al.
6. Plasminogen Activation in Ovarian Cancer
B. Casslén and B. Astedt
7. Increased Urokinase-Plasminogen Activator (u-PA) Expression Correlates with the Aggressive Phenotype in Human Prostate Cancer Cells
J.M. Kozlowski et al.
8. Epidermal Growth Factor Receptor and Plasminogen Activators in Bladder Cancer
D.J. Thomas and D.E. Neal
9. Role of u-PA in Determining the Biological Behavior of Gastric Cancer
S. Takai et al.
10. u-PA Levels in Plasma, Urine, and Tissues of Patients with Cancer of the Digestive Tract
N. Nishino, S. Baba, and A. Takada
11. u-PA:t-PA Ratio as Determinator in Gastrointestinal Cancer
H.W. Verspaget
12. Plasminogen Activators in Osteoblastic Cells
L.C. Carpio and R. Dziak
13. u-PA as an Autocrine Mitogen in Human Melanoma Cells
B.R. Binder and M. Ruthner
14. PAI-1 and PAI-2 in Leukemic Patients
B. Bennett and A. Croll
Part 2: Interventions
A. Exercise
15. Effects of Physical Training and Smoking Cessation on PAI Levels
J.-C. Gris and J.-F. Schved
16. Fibrinolytic Response to Strenuous Physical Exercise
J.-B. Hansen
B. Diet
17. Hyperlipidemia and Reduced Fibrinolysis-Diet or Drugs?
P. Andersen
18. Effect of Fish Oil on Some Parameters of Fibrinolysis
O. Haglund, T.G.P. Saldeen, and J.L. Mehta
19. Diet and Fibrinolysis, with Special Reference to the Effects of Fiber Intake
T.K. Nilsson et al.
C. Direct Thrombolytic Agents
20. Conjunctive Thrombolytic and Antithrombotic Therapy for Acute Myocardial Infarction
H.J. Rapold
21. Platelet Activation during Thrombolytic Therapy in Unstable Angina
M. Reilly and D.J. Fitzgerald
22. Paradoxic Prothrombotic Effects during Pharmacologic Thrombolysis
G.A. Ewald and P.R. Eisenberg
23. Plasma Fibrinopeptide A and B Levels May Not Be Specific Markers of Thrombin Activity during Pharmacologic Thrombolysis
J.I. Weitz
24. Efficient Coronary Thrombolysis Is Dependent on Concentrations of Free t-PA
C.L. Lucore
25. Thrombolytic Therapy in Patients with Acute Massive Pulmonary Embolism
M. Verstraete
26. Thrombolysis in Cerebrovascular Ischemia
G.J. del Zoppo
D. Indirect Thrombolytic Agents
27. Use of Ancrod in Patients with Heparin-Induced Thrombocytopenia and during Cardiopulmonary Bypass Surgery
K. Aogaichi
28. Therapy with Ancrod in Acute Ischemic Stroke
D.E. Levy
29. Fibrinolytic and Clinical Effects of Ancrod in Systemmic Lupus Erythematosus and Acute Ischemic Stroke
P. Glas-Greenwalt
30. Fibrinolytic Response to DDAVP and Its Potential Clinical Relevance
E. Törnebohm-Roche
E. Heparin and Others
31. Interaction of Heparin with Plasminogen Activators and Plasminogen In Vitro
D.C. Rijken, G.A.W. de Munk, and A.F.H. Jie
32. Profibrinolytic Effects of Modified Heparins
R. Porta and R. Pescador
33. Disease and Drug Modulation of Fibrinolysis
J. Fareed et al.
Part 3: Future
34. Genetically Engineered New Thrombolytic Agents
H.R. Lijnen and D. Collen
35. Antibody Targeting of Plasminogen Activators
M.S. Runge, K.W. Harris, and C. Bode
36. The Potential Use of Anti-PAI-1 Antibodies as Adjuvants in Thrombolytic Therapy
M. Levi and B.J. Biemond
37. Vampire Bat Salivary Plasminogen Activator
S.J. Gardell
38. Stimulation of Indigenous Fibrinolysis: A Novel Approach of Prevention from Thrombosis
G. Dooijewaard and C. Kluft
39. The Potentials of Retinoids as Stimulators of Endogenous Tissue-Type Plasminogen Activator
T. Kooistra
40. Growth Factor Mechanisms and Cancer Therapy
K.R. Meehan and L.R. Zacharski

About the author

Pia Glas-Greenwalt, M.D., is Director of the Fibrinolysis/Special Coagulation Laboratory at the Good Samaritan Hospital and Affiliated with the Department of Internal Medicine at the University of Cincinnati Medical Center, Cincinnati, Ohio.

Summary

First published in 1995: Fibrinolysis in Disease reviews the state of the art of basic and clinical aspects of the fibrinolytic enzyme system. The text, authored by outstanding and internationally known investigators, is presented in two books. The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities discusses the molecular biology of the system's key components and their fundamental roles in a variety of thrombotic and metabolic disorders. Molecular and Hemovascular Aspects of Fybrinolysis presents the latest findings and concepts of the association between plasminogen activator (u-PA) overexpression and abnormal growth regulation in a variety of solid tumors and in leukemia. One chapter deals with various successful interventions in thrombogenic mechanisms, ranging from exercise and diet to anticoagulants and direct and indirect thrombolytic agents. It concludes with a projection of exciting, novel treatment modalities in thrombotic and malignant diseases.

Product details

• Authors: Pia Glas-Greenwalt
• Assisted by: Pia Glas-Greenwalt (Editor)
• Publisher: Taylor & Francis Ltd.
• Languages: English
• Product format: Hardback
• Release: 31.05.2019, delayed
• EAN: 9780367244194
• ISBN: 978-0-367-24419-4
• No. of pages: 268
• Series: Routledge Revivals
• Subject: Natural sciences, medicine, IT, technology > Medicine > Clinical medicine